Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study-Reference-Cited by-同舟云学术

Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study

Published:2023-10 Issue:10 Volume:5 Page:e584-e593
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Cho Jiacai^ORCID,Shen Liang^ORCID,Huq Molla,Kandane-Rathnayake Rangi^ORCID,Golder Vera^ORCID,Louthrenoo Worawit^ORCID,Chen Yi-Hsing^ORCID,Hamijoyo Laniyati^ORCID,Luo Shue-Fen^ORCID,Wu Yeong-Jian J^ORCID,Zamora Leonid^ORCID,Li Zhanguo^ORCID,Sockalingam Sargunan^ORCID,Katsumata Yasuhiro^ORCID,Harigai Masayoshi^ORCID,Hao Yanjie^ORCID,Zhang Zhuoli^ORCID,Basnayake Duminda,Chan Madelynn^ORCID,Kikuchi Jun^ORCID,Takeuchi Tsutomu^ORCID,Bae Sang-Cheol^ORCID,Oon Shereen^ORCID,O'Neill Sean^ORCID,Goldblatt Fiona^ORCID,Ng Kristine Pek Ling,Law Annie,Tugnet Nicola,Kumar Sunil,Tee Cherica,Tee Michael,Ohkubo Naoaki,Tanaka Yoshiya,Navarra Sandra V^ORCID,Lau Chak Sing^ORCID,Hoi Alberta^ORCID,Morand Eric F^ORCID,Nikpour Mandana^ORCID,Lateef Aisha^ORCID

Funder

Bristol-Myers Squibb Company

Eli Lilly and Company

AstraZeneca PLC

GlaxoSmithKline Plc

Janssen Global Services LLC

EMD Serono Inc

Janssen Research and Development LLC

AstraZeneca Pty Ltd

GlaxoSmithKline Inc

UCB Group

Publisher